Benlysta mg solution for injection in pre-filled syringe. 2. available information, dose adjustment is not required in patients with mild, moderate or severe. Learn about BENLYSTA (belimumab), an FDA-approved prescription infusion or self-injectable lupus medication to help treat your Request your FREE Info Kit. Belimumab (Benlysta) is a biologic reference with prescribing information, dosage, medication administration, and possible side effects.

Author: Jull Kagagrel
Country: Cambodia
Language: English (Spanish)
Genre: Spiritual
Published (Last): 17 January 2007
Pages: 56
PDF File Size: 8.6 Mb
ePub File Size: 3.64 Mb
ISBN: 323-9-51314-668-4
Downloads: 75000
Price: Free* [*Free Regsitration Required]
Uploader: Vumuro

It significantly increased American College of Rheumatology ACR 20 responses at week 24, especially in patients with high disease activity, positive rheumatoid factor, no anti-tumor necrosis factor TNF treatment experience and those who had failed methotrexate therapy. Careful patient selection may be necessary for belimumab to achieve optimal clinical outcomes in RA.

The effect of belimumab on the reduction of SLE disease activity or flares was not significant. In the subgroup An experimental medicine, randomised, placebo-controlled phase 2 trial.

B-cell-targeted treatment for multiple sclerosis: GSK; revised July Seizures — in the absence of offending drugs or known metabolic derangement, e.

Changes in gene expression were consistent with mechanism of action and showed that clinical response to treatment with belimumab was associated with a significant decrease in pro-fibrotic genes and pathways. In a phase II, randomized, double-blind, placebo-controlled, dose-ranging study, Wallace and colleagues evaluated the safety, tolerability, biological activity, and effectiveness of belimumab in combination with standard of care therapy SOC in patients with active SLE.


The patient was started on add-on belimumab with quasi-immediate effect on the proteinuria, making it possible to decrease the dosage of the other immunosuppressants and gradually stop them, even the GCS.

Most currently available molecules target TNF-alpha with different strategies i.

Belimumab (Benlysta)

Biopsy of the kidney confirmed the diagnosis of membranous lupus nephritis. Circulating antibody-secreting cells were benlywta using enzyme-linked immunospot assay. Benlysta belimumab for injection, for subcutaneous use. In both cases, MMF, as induction therapy, was poorly tolerated because of gastro-intestinal GI toxicity. The authors concluded that lupus nephritis is a potentially devastating complication of SLE. Belimumab was well-tolerated in the treatment of RA over 24 weeks.

Autologous stem cell transplantation showed the best therapeutic efficacy on skin and internal organs, and looks very promising, as modification of transplantation immunosuppression is decreasing the early high mortality.

Belimumab was added to concomitant standard therapy.

The analysis was performed on all randomized patients who received study agent. These investigators assessed safety, efficacy, and differential gene expression.

Further, small molecules have been recently developed to target intra-cellular signaling, such as janus kinases for tofacitinib, the first FDA-approved small molecule for RA. This was a single-case study; its findings need to be validated by well-designed studies. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.

Biologic agents for the treatment of lupus nephritis are being studied, including belimumab which was recently approved for non-renal SLE. The rates of adverse events and serious adverse events were similar in the belimumab and placebo groups. FDA; March 11, For example, reducing relapse risk and glucocorticoid toxicity; newer therapies are needed. In both human and murine studies, B cell-directed therapies appeared to have clinical and serologic beneficial effects including a decrease in the anti-phospholipid antibody titers after treatment.


Pleuritis — convincing history of pleuritic pain or rub heard by a physician or evidence of pleural effusion.

B-cell depletion using rituximab has been of benefit, mainly in relation to extra-glandular features, and to some extent in relation to hypo-salivation where there is still residual salivary function.

These researchers stated that potential newer drugs are emerging following a better understanding of disease mechanisms and the availability of targeted therapies to B cells, T cells, pro-inflammatory cytokines and complement.

Antibody-Mediated Rejection in Lung Transplantation Hulbert and colleagues stated that there is increasing recognition of the importance of antibody-mediated rejection AMR after lung transplantation.

Belimumab (Benlysta) – Medical Clinical Policy Bulletins | Aetna

Current data suggests that conventional approaches are of sub-optimal efficacy, but emerging therapeutic agents with diverse biological mechanisms offer promise for improved AMR treatment. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Dexamethasone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram.

Oral or nasopharyngeal ulceration, usually painless, observed by a physician. Belimumab for the treatment of recalcitrant cutaneous lupus. Skin rash as a result of unusual reaction prescribkng sunlight, y patient history or physician observation.